【レポートの概要（一部）】
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Disease overview
• Understanding the disease
• Etiology
• Signs and symptoms
• Diagnosis
• Management
• Economic burden
• Epidemiology
PART 06: Pipeline portfolio
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Market segmentation by type of disease
• RA
• MS
• PsA
• IBD
• AS
• SLE
• Global RA drugs market
• Clinical trials for RA
• Global MS drugs market
• Global PsA drugs market
• Global IBD drugs market
• Global AS drugs market
• Global SLE drugs market
PART 09: Market segmentation by mechanism of action
• TNF inhibitors
• IL-1 blockers
• COX inhibitors
• PDE4 inhibitors
• Others
PART 10: Market segmentation by drug class
• DMARDs
• NSAIDs
• Corticosteroids
• Analgesics
• Immunosuppressants
• Others
PART 11: Market segmentation by type of molecule
• Biologics
• Small molecules
PART 12: Market segmentation by ROA
• Oral
• Parenteral
• Topical
PART 13: Market segmentation by dosage form
• Solid
• Liquid
• Semi-solid
PART 14: Geographical segmentation
• Autoimmune diseases drugs market in the Americas
• Autoimmune diseases drugs market in US
• Autoimmune diseases drugs market in EMEA
• Autoimmune diseases drugs market in APAC
• Autoimmune diseases drugs market in Japan
• Autoimmune diseases drugs market in China
PART 15: Market drivers
• Rising prevalence of autoimmune diseases
• Growing older population
• Dominance of biologics
• Unmet medical needs
• Promising pipeline
PART 16: Impact of drivers
PART 17: Market challenges
• Increasing cost of biologics
• Loss of patent exclusivity of branded therapies
• Complex nature of autoimmune diseases
• Preference for CAMs
• Adverse effects
PART 18: Impact of drivers and challenges
PART 19: Market trends
• Emergence of biosimilars
• Patient assistance programs
• Increase in public awareness programs
• Strategic alliances
• Popularity of off-label and traditional treatment options
PART 20: Vendor landscape
• Competitive scenario
• Market analysis 2015
• AbbVie
• Johnson & Johnson
• Biogen
• Amgen
• Pfizer
• F. Hoffmann-La Roche
• Other prominent vendors
PART 21: Appendix
• List of abbreviations
PART 22: Explore Technavio
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: Etiology of autoimmune diseases
Exhibit 03: Signs and symptoms of autoimmune diseases
Exhibit 04: Diagnostic methods for autoimmune diseases
Exhibit 05: Non-pharmacological therapies used for autoimmune diseases
Exhibit 06: Pharmacotherapy therapies used for autoimmune diseases
Exhibit 07: Top drugs for autoimmune diseases
Exhibit 08: Average annual treatment costs of RA in US and Europe 2014 ($ billions)
Exhibit 09: Average annual treatment costs of MS across countries 2014 ($ billions)
Exhibit 10: Average annual treatment costs of PsA across countries 2014 ($ billions)
Exhibit 11: Prevalence and incidence of SLE
Exhibit 12: Pipeline molecules for RA
Exhibit 13: Pipeline molecules for MS
Exhibit 14: Pipeline molecules for PsA
Exhibit 15: Pipeline molecules for CD
Exhibit 16: Pipeline molecules for UC
Exhibit 17: Pipeline molecules for SLE
Exhibit 18: Global autoimmune diseases drugs market 2015-2020 ($ billions)
Exhibit 19: Five forces analysis
Exhibit 20: Global autoimmune diseases drugs market segmentation by type of disease
Exhibit 21: Global autoimmune diseases drugs market by type of disease 2015
Exhibit 22: Global autoimmune diseases drugs market: YoY revenue and growth based on autoimmune diseases 2015-2020
Exhibit 23: Global RA drugs market 2015-2020 ($ billions)
Exhibit 24: Global RA drugs market by drug class 2015
Exhibit 25: Top-vendor offerings for global RA drugs market
Exhibit 26: RA clinical trial by Phase 2015
Exhibit 27: RA clinical trial by status 2015
Exhibit 28: Drivers and challenges of global RA drugs market
Exhibit 29: Global MS drugs market 2015-2020 ($ billions)
Exhibit 30: Global MS drugs market by molecule type 2015
Exhibit 31: Top-vendor offerings for global MS drugs market
Exhibit 32: Drivers and challenges of global MS drugs market
Exhibit 33: Global PsA drugs market 2015-2020 ($ billions)
Exhibit 34: Global PsA drugs market segmentation by MOA 2015
Exhibit 35: Top-vendor offerings for global PsA drugs market
Exhibit 36: Drivers and challenges of global PsA drugs market
Exhibit 37: Global IBD drugs market 2015-2020 ($ billions)
Exhibit 38: Global IBD drugs market by type of disease 2015
Exhibit 39: Global IBD drugs market by drug class 2015
Exhibit 40: Top-vendor offerings for global IBD drugs market
Exhibit 41: Drivers and challenges of global IBD drugs market
Exhibit 42: Global AS drugs market 2015-2020 ($ billions)
Exhibit 43: Global AS drugs market by MOA 2015
Exhibit 44: Top-vendor offerings for global AS drugs market
Exhibit 45: Drivers and challenges of global AS drugs market
Exhibit 46: Global SLE drugs market 2015-2020 ($ billions)
Exhibit 47: Drivers and challenges of global SLE drugs market
Exhibit 48: Global autoimmune diseases drugs market segmentation by MOA
Exhibit 49: Average percentage of patients receiving TNF inhibitors 2010 and 2015
Exhibit 50: Global autoimmune diseases drugs market share by MOA 2015
Exhibit 51: Global autoimmune diseases drugs market segmentation by drug class
Exhibit 52: Examples of non-biologic DMARDs and biologic DMARDs for autoimmune diseases
Exhibit 53: NSAIDs used to treat autoimmune diseases
Exhibit 54: Global autoimmune diseases drugs market by drug class 2015
Exhibit 55: Global autoimmune diseases drugs market segmentation by type of molecule
Exhibit 56: Global autoimmune diseases biologics market 2015-2020 ($ billions)
Exhibit 57: Global autoimmune diseases small molecules market 2015-2020 ($ billions)
Exhibit 58: Global autoimmune diseases drugs market by type of molecules 2015
Exhibit 59: Global autoimmune diseases drugs market segmentation by ROA
Exhibit 60: Global autoimmune diseases drugs market segmentation by ROA 2015
Exhibit 61: Global autoimmune diseases drugs market segmentation by dosage form
Exhibit 62: Global autoimmune disease drugs market segmentation by dosage form 2015
Exhibit 63: Global autoimmune diseases drugs market segmentation by geography 2015
Exhibit 64: Global autoimmune diseases drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 65: Autoimmune diseases drugs market in the Americas 2015-2020 ($ billions)
Exhibit 66: Autoimmune diseases drugs market in America by country 2015
Exhibit 67: Autoimmune diseases drugs market in US 2015-2020 ($ billions)
Exhibit 68: Drivers and challenges for autoimmune diseases drugs market in the US
Exhibit 69: Autoimmune diseases drugs market in EMEA 2015-2020 ($ billions)
Exhibit 70: Autoimmune diseases drugs market in APAC 2015-2020 ($ billions)
Exhibit 71: Autoimmune diseases drugs market in Japan 2015-2020 ($ billions)
Exhibit 72: Drivers and challenges for autoimmune diseases drugs market in Japan
Exhibit 73: Autoimmune diseases drugs market in China 2015-2020 ($ billions)
Exhibit 74: Global autoimmune diseases drugs market YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 75: Population aged 60 years and over ($ millions)
Exhibit 76: Biologics approval timeline by US FDA
Exhibit 77: Some pipeline molecules under phases of development for autoimmune diseases
Exhibit 78: Impact of drivers
Exhibit 79: Average annual treatment cost of adalimumab, etanercept, and infliximab 2014 ($ millions)
Exhibit 80: Approval and patent expiries of top selling biologics
Exhibit 81: CAM therapies for autoimmune diseases
Exhibit 82: Usage of CAM therapies among individuals in US 2014
Exhibit 83: Adverse effects associated with autoimmune disease therapies
Exhibit 84: Impact of drivers and challenges
Exhibit 85: Patient assistance programs for autoimmune diseases drugs
Exhibit 86: Revenue share of major companies for autoimmune diseases 2015
Exhibit 87: YoY Sales comparison of top drugs 2013-2015 ($ billions)
Exhibit 88: AbbVie: Product segmentation by revenue 20150
Exhibit 89: AbbVie: YoY growth rate and revenue of HUMIRA 2013-2015 ($ billions)
Exhibit 90: AbbVie: YoY growth rate and revenue of HUMIRA in US 2013-2015 ($ billions)
Exhibit 91: AbbVie: YoY growth rate and revenue of HUMIRA in ROW 2013-2015 ($ billions)
Exhibit 92: Sales of HUMIRA in major markets
Exhibit 93: AbbVie: Key takeaways
Exhibit 94: Johnson & Johnson: Segmentation of key autoimmune diseases drugs 2014
Exhibit 95: Johnson & Johnson: YoY growth rate and revenue of Remicade 2013-2014 ($ billions)
Exhibit 96: Johnson & Johnson: YoY growth rate and revenue of Remicade in US 2013-2015 ($ billions)
Exhibit 97: Johnson & Johnson: YoY growth rate and revenue of Remicade in ROW 2013-2015 ($ billions)
Exhibit 98: Johnson & Johnson: YoY growth rate and revenue of Stelara 2013-2015 ($ billions)
Exhibit 99: Johnson & Johnson: YoY growth rate and revenue of Stelara in US 2013-2015 ($ billions)
Exhibit 100: Johnson & Johnson: YoY growth rate and revenue of Stelara in ROW 2013-2015 ($ millions)
Exhibit 101: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 102: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria in US 2013-2015 ($ millions)
Exhibit 103: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria in ROW 2013-2015 ($ millions)
Exhibit 104: Johnson & Johnson: Key takeaways
Exhibit 105: Biogen: Product segmentation of key autoimmune diseases drugs by revenue 2015
Exhibit 106: Top selling autoimmune diseases drugs
Exhibit 107: Biogen: YoY growth rate and revenue of Tecfidera 2013-2015 ($ billions)
Exhibit 108: Biogen: YoY growth rate and revenue of Avonex 2013-2015 ($ billions)
Exhibit 109: Biogen: YoY growth rate and revenue of Tysabri 2013-2015 ($ billions)
Exhibit 110: Biogen: YoY revenue of Plegridy 2014-2015 ($ millions)
Exhibit 111: Biogen: YoY growth rate and revenue of Fampyra 2013-2015 ($ millions)
Exhibit 112: Biogen: Key takeaways
Exhibit 113: Amgen: YoY growth rate and revenue of Enbrel in US and Canada 2013-2015 ($ billions)
Exhibit 114: Amgen: YoY growth rate and revenue of Enbrel in US 2013-2015 ($ billions)
Exhibit 115: Amgen: YoY growth rate and revenue of Enbrel in Canada 2013-2015 ($ millions)
Exhibit 116: Amgen: Key takeaways
Exhibit 117: Pfizer: Autoimmune diseases drugs product segmentation by revenue 2014
Exhibit 118: Top selling autoimmune diseases drugs
Exhibit 119: Pfizer: YoY growth rate and revenue of Enbrel (outside US and Canada) 2013-2015 ($ billions)
Exhibit 120: Pfizer: YoY growth rate and revenue of Celebrex 2013-2015 ($ billions)
Exhibit 121: Pfizer: YoY growth rate and revenue of Xeljanz 2012-2014 ($ millions)
Exhibit 122: Pfizer: Key takeaways
Exhibit 123: Top selling autoimmune diseases drugs
Exhibit 124: F. Hoffmann-La Roche: YoY growth rate and revenue of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 125: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 20155
Exhibit 126: F. Hoffmann-La Roche: YoY growth rate and revenue of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions)
Exhibit 127: F. Hoffmann-La Roche: YoY growth rate and revenue of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)
Exhibit 128: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
Exhibit 129: F. Hoffmann-La Roche: Key takeaways
【レポート販売概要】
■ タイトル：自己免疫疾患用薬の世界市場2016-2020■ 英文：Global Autoimmune Drugs Market 2016-2020
■ 発行日：2016年3月18日
■ 調査会社：Technavio
■ 商品コード：IRTNTR9055
■ 調査対象地域：グローバル
- 呼吸機能測定装置の世界市場：パイプラインレビュー2015Respiratory Measurement Devices - Pipeline Review, 2015 Summary GlobalData's Medical Devices sector report, “Respiratory Measurement Devices - Pipeline Review, 2015" provides an overview of Respiratory Measurement Devices currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. Th …
- 世界におけるコンピュータ数値制御（CNC）ソリューション市場TechNavio's analysts forecast the Global Computer Numerical Control Solutions market to grow at a CAGR of 5.19 percent over the period 2012-2016. One of the key factors contributing to this market growth is the upsurge in the Machine Tool industry. The Global Computer Numerical Control Solutions market has also been witnessing steady demand from the retrofit segment. However, the need for increase …
- 洋上風力発電の世界市場予測（～2022年）：風力タービン、土台、電気インフラ“The offshore wind market is projected to grow at a CAGR of 15.32% from 2017 to 2022” The offshore wind market is projected to reach USD 55.11 billion by 2022, at a CAGR of 15.32% from 2017 to 2022. The offshore wind market has been rapidly growing, especially in Europe as it contributed the European Union (EU) to meet its renewable energy targets for 2020. The global demand for electric power is …
- 無人地上センサ（UGS）の世界市場2018-2022107 pages, November 2018 About this market The need for small, lightweight, and low power solutions in the military and aerospace industry is boosting the demand for nanotechnology and microelectromechanical systems (MEMS). This have encouraged manufacturers around the world to develop innovative miniaturized electronics. The low-cost sensors are less sophisticated and are mainly used for routine …
- 組織検査の世界市場：免疫組織化学、in situハイブリダイゼーション、デジタルパソロジー、ワークフロー管理、特殊染色法The global tissue diagnostics market is valued at USD 3,202.5 Million in 2015 and expected to reach USD 4,471.1 Million by 2020, at a CAGR of 6.9% from 2015 to 2020. A major driver for the growth of the tissue diagnostics industry is the increasing prevalence of cancer. On the other hand, the high degree of consolidation, stringent regulatory requirements, and lack of budgets are restraining the g …
- コンテナリースの世界市場2019-2023About this market The growth in the global demand for refrigerated transportation is driving growth in the market. The growth of the market is majorly attributed to the increase in the adoption of cold chain solutions, owing to benefits such as ensuring the safe transportation of temperature sensitive and perishable products. Technavio’s analysts have predicted that the container leasing market wi …
- LTE基地局の世界市場2017-2021About LTE Base Station Market LTE base stations are used for high-speed communication networks. Technavio’s analysts forecast the global LTE base station market to grow at a CAGR of 17.01% during the period 2017-2021. [Covered in this report] The report covers the present scenario and the growth prospects of the global LTE base station market for 2017-2021. To calculate the market size, the report …
- M-キシリレン・ジイソシアネートの世界市場M-Xylylene Diisocyanate (CAS 3634-83-1) Market Research Report 2013 presents comprehensive data on m-xylylene diisocyanate markets globally and regionally (Europe, Asia, North America etc.) The M-Xylylene Diisocyanate (CAS 3634-83-1) Market Research Report 2013 includes m-xylylene diisocyanate description, covers its application areas and related patterns. It overviews m-xylylene diisocyanate mark …
- インジウムスズ酸化物（ITO）の世界市場Indium Tin Oxide (CAS 50926-11-9) Market Research Report 2014 presents comprehensive data on indium tin oxide markets globally and regionally (Europe, Asia, North America etc.) The report includes indium tin oxide description, covers its application areas and related patterns. It overviews indium tin oxide market, names indium tin oxide producers and indicates its suppliers. Besides, the report pr …
- 世界のコジェネレーション設備市場動向（2012-2016）TechNavio's analysts forecast the Global Cogeneration Equipment market to grow at a CAGR of 9.4 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for electric power. The Global Cogeneration Equipment market has also been witnessing the increased use of cogeneration technology in the renewable energy area. However, the volatility o …
- プロバイオティクス飲料の世界市場2018-202296 Pages, November 2018 About this market The demand for probiotic drinks is increasing among consumers due to the rising awareness about their health and metabolic benefits. This is encouraging market vendors to invest more in the development of probiotic drinks products. Technavio’s analysts have predicted that the global probiotic drinks market will register a CAGR of almost 7% by 2022. Market …
- フットウェアの世界市場2019-2023Global Footwear Market: About this market The footwear offered in the market is made up of various raw materials such as leather, natural rubber, synthetic rubber, ethylene-vinyl acetate (EVA), polyvinyl chloride (PVC), polyurethane (PU), and textiles. Technavio’s footwear market analysis considers sales from both athletic footwear and non-athletic footwear. Our analysis also considers the sales o …
- 世界のアルツハイマー病治療薬・診断市場予測Alzheimer’s medicine – your guide to technologies, trends and revenues Where is the Alzheimer’s disease treatment market heading? Visiongain’s new report gives you revenue predictions for those drugs and diagnostic tests from 2014, helping you stay ahead. Our 182-page report provides 131 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. …
- フーズボール用品の世界市場About Foosball EquipmentFoosball, which is also known as table football or table soccer, is a table top game which is played by players turning rods fixed on top of a playing box and attached to miniature figures of players, in order to flick the ball and strike it towards the goal. Technavio’s analysts forecast the global foosball equipment market to grow at a CAGR of 2.39% during the period 2017 …
- 世界のAMC CPUカード市場動向（2012-2016）TechNavio's analysts forecast the Global AMC CPU Cards market to grow at a CAGR of 20.2 percent over the period 2012-2016. One of the key factors contributing to this market growth is the hot swap capability of AMCs. The Global AMC CPU Cards market has also been witnessing the increase in the adoption of ATCA platforms integrated with AMC modules by TEMs. However, the slow adoption rate could pose …
